Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2017–2021 2023 [https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-28-no-3/index.html. Accessed 9/14/2023.

Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564-74;10.1016/s0140-6736(13)61530-5.

Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45. https://doi.org/10.1016/s0140-6736(08)61311-2.

Article  PubMed  Google Scholar 

Jennings JM, Wagner J, Tilchin C, Schumacher CM, Thornton N, Hamill MM et al. Methamphetamine Use, Syphilis, and Specific Online Sex Partner Meeting Venues Are Associated With HIV Status Among Urban Black Gay and Bisexual Men Who Have Sex Men. Sex Transm Dis. 2021;48(8s):S32-s9;10.1097/olq.0000000000001452.

Compton WM, Jones CM. Substance Use among Men Who Have Sex with Men. N Engl J Med. 2021;385(4):352-6;10.1056/NEJMra2033007.

Edeza A, Bazzi A, Salhaney P, Biancarelli D, Childs E, Mimiaga MJ, et al. HIV Pre-exposure Prophylaxis for people who inject drugs: the context of co-occurring injection- and sexual-related HIV risk in the U.S. Northeast. Subst Use Misuse. 2020;55(4):525–33. https://doi.org/10.1080/10826084.2019.1673419.

Article  PubMed  Google Scholar 

Brookmeyer KA, Haderxhanaj LT, Hogben M, Leichliter J. Sexual risk behaviors and STDs among persons who inject drugs: A national study. Prev Med. 2019;126:105779;10.1016/j.ypmed.2019.105779.

Burnett JC, Broz D, Spiller MW, Wejnert C, Paz-Bailey G. HIV infection and HIV-Associated behaviors among persons who inject drugs – 20 cities, United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(1):23–8. https://doi.org/10.15585/mmwr.mm6701a5.

Article  PubMed  PubMed Central  Google Scholar 

Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD et al. Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs-Massachusetts, 2015–2018. Am J Public Health. 2020;110(1):37–44;10.2105/ajph.2019.305366.

Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. Aids. 2020;34(14):1997–2005;10.1097/qad.0000000000002673.

Jones CM, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Ann N Y Acad Sci. 2022;1508(1):3–22;10.1111/nyas.14688.

Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L et al. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397(10279):1139-50;10.1016/s0140-6736(21)00391-3.

Biello KB, Mimiaga MJ, Valente PK, Saxena N, Bazzi AR. The Past, Present, and Future of PrEP implementation Among People Who Use Drugs. Curr HIV/AIDS Rep. 2021;18(4):328 – 38;10.1007/s11904-021-00556-z.

Kuo I, Olsen H, Patrick R, Phillips G 2nd, Magnus M, Opoku J et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13;10.1016/j.drugalcdep.2016.02.044.

Shrestha R, Altice FL, Huedo-Medina TB, Karki P, Copenhaver M. Willingness to Use Pre-exposure Prophylaxis (PrEP): an empirical test of the information-motivation-behavioral skills (IMB) model among high-risk drug users in treatment. AIDS Behav. 2017;21(5):1299–308. https://doi.org/10.1007/s10461-016-1650-0.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Continuity and coordination of care: a practice brief to support implementation of the WHO Framework on integrated people-centred health services. 2018.

Desai M, Field N, Grant R, McCormack S. Recent advances in pre-exposure prophylaxis for HIV. BMJ. 2017;359(j5011). https://doi.org/10.1136/bmj.j5011.

Centers for Disease Control and Prevention. PrEP for HIV Prevention in the U.S. 2021 [https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/PrEP-for-hiv-prevention-in-the-US-factsheet.html#anchor_1681392749. Accessed.

Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5):e048478. https://doi.org/10.1136/bmjopen-2020-048478.

Article  Google Scholar 

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. https://doi.org/10.1016/s0140-6736(13)61127-7.

Article  PubMed  Google Scholar 

Bazzi AR, Drainoni ML, Biancarelli DL, Hartman JJ, Mimiaga MJ, Mayer KH, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health. 2019;19(1):31. https://doi.org/10.1186/s12889-018-6314-8.

Article  PubMed  PubMed Central  Google Scholar 

Shrestha R, Copenhaver M. Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. Front Public Health. 2018;6:195;10.3389/fpubh.2018.00195.

Okafor CN, Gorbach PM, Ragsdale A, Quinn B, Shoptaw S. Correlates of Preexposure Prophylaxis (PrEP) Use among Men Who Have Sex with Men (MSM) in Los Angeles, California. J Urban Health. 2017;94(5):710-5;10.1007/s11524-017-0172-z.

Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7(4):210-9;10.1007/s11904-010-0062-4.

Martinez-Cajas JL, Torres J, Mueses HF, Plazas PC, Arrivillaga M, Gomez SA et al. Applying implementation science frameworks to identify factors that influence the intention of healthcare providers to offer PrEP care and advocate for PrEP in HIV clinics in Colombia: a cross-sectional study. Implementation Science Communications. 2022;3(1):31;10.1186/s43058-022-00278-2.

Nilsen P, Bernhardsson S. Context matters in implementation science: a scoping review of determinant frameworks that describe contextual determinants for implementation outcomes. BMC Health Services Research. 2019;19(1):189;10.1186/s12913-019-4015-3.

Damschroder L, Reardon CM, Widerquist MAO, Lowery JC. The Updated Consolidated Framework for Implementation Research: CFIR 2.0. 2022.

Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for specifying and reporting. Implementation Science. 2013;8(1):139;10.1186/1748-5908-8-139.

Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65–76;10.1007/s10488-010-0319-7.

Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, Mayer KH, Mimiaga M, Patel R et al. Defining the HIV pre-exposure prophylaxis care continuum. Aids. 2017;31(5):731-4;10.1097/qad.0000000000001385.

Burns PA, Omondi AA, Monger M, Ward L, Washington R, Sims Gomillia CE et al. Meet Me Where I Am: An Evaluation of an HIV Patient Navigation Intervention to Increase Uptake of PrEP Among Black Men Who Have Sex with Men in the Deep South. J Racial Ethn Health Disparities. 2022;9(1):103 – 16;10.1007/s40615-020-00933-1.

Saberi P, Berrean B, Thomas S, Gandhi M, Scott H. A Simple Pre-Exposure Prophylaxis (PrEP) Optimization Intervention for Health Care Providers Prescribing PrEP: Pilot Study. JMIR Form Res. 2018;2(1);10.2196/formative.8623.

Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH. Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States. Open Forum Infect Dis. 2019;6(10);10.1093/ofid/ofz365.

Smith JD, Li DH, Merle JL, Keiser B, Mustanski B, Benbow ND. Adjunctive Interventions: Change Methods Directed at Recipients That Support Uptake and Use of Health Innovations. Implementation Science. 2024;19(1);10.1186/s13012-024-01345-z.

Merle JL, Benbow N, Li D, Zapata J, Quieroz A, Zamantakis A, Mckay V, Kaiser B, Villamar J, Mustanksi B, Smith J. Improving Delivery and Use of HIV Pre-Exposure Prophylaxis in the US: A Systematic Review of Change Methods. AIDS and Behavior. 2024;10.1007/s10461-024-04331-0.

Desrosiers A, Levy M, Dright A, Zumer M, Jallah N, Kuo I et al. A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC. AIDS Behav. 2019;23(1):105 – 15;10.1007/s10461-018-2264-5.

Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR et al. A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS. 2018;32(3):104 – 11;10.1089/apc.2017.0255.

Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, Anderson PL, Lester R et al. Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Clin Infect Dis. 2019;68(12):2010-7;10.1093/cid/ciy810.

Colson PW, Franks J, Wu Y, Winterhalter FS, Knox J, Ortega H et al. Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY. AIDS Behav. 2020;24(12):3436-55;10.1007/s10461-020-02901-6.

Gebru NM, Canidate SS, Liu Y, Schaefer SE, Pavila E, Cook RL et al. Substance Use and Adherence to HIV Pre-Exposure Prophylaxis in Studies Enrolling Men Who Have Sex with Men and Transgender Women: A Systematic Review. AIDS Behav. 2023;27(7):2131-62;10.1007/s10461-022-03948-3.

Guy D, Doran J, White TM, van Selm L, Noori T, Lazarus JV. The HIV pre-exposure prophylaxis continuum of care among women who inject drugs: A systematic review. Front Psychiatry. 2022;13:951682;10.3389/fpsyt.2022.951682.

Mistler CB, Copenhaver MM, Shrestha R. The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. AIDS and Behavior. 2021;25(5):1490 – 506;10.1007/s10461-020-02988-x.

Glick JL, Russo R, Jivapong B, Rosman L, Pelaez D, Footer KH, et al. The PrEP care continuum among cisgender women who sell sex and/or use drugs globally: a systematic review. AIDS Behav. 2020;24:1312–33.

Article  PubMed  PubMed Central  Google Scholar 

Zhang C, McMahon J, Simmons J, Brown LL, Nash R, Liu Y. Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis. AIDS Behav. 2019;23(10):2641-53;10.1007/s10461-019-02573-x.

Li DH, Benbow N, Keiser B, Mongrella M, Ortiz K, Villamar J et al. Determinants of Implementation for HIV Pre-exposure Prophylaxis Based on an Updated Consolidated Framework for Implementation Research: A Systematic Review. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2022;90(S1):S235-S46;10.1097/qai.0000000000002984.

Merle JL, Li D, Keiser B, Zamantakis A, Queiroz A, Gallo CG et al. Categorising implementation determinants and strategies within the US HIV implementation literature: a systematic review protocol. BMJ Open. 2023;13(3):e070216;10.1136/bmjopen-2022-070216.

Software VERBI. MAXQDA 2022 computer program. 2021;VERBI Software, Berlin.

National Institute on Drug Abuse. Commonly Used Drugs Charts 2020 [https://nida.nih.gov/research-topics/commonly-used-drugs-charts. Accessed 9/10/2023.

Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implementation Science. 2011;6(1):42;10.1186/1748-5908-6-42.

Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10:21;10.1186/s13012-015-0209-1.

Atkins L, Francis J, Islam R, O’Connor D, Patey A, Ivers N et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implementation Science. 2017;12(1):77;10.1186/s13012-017-0605-9.

Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implementation Science. 2012;7(1):37;10.1186/1748-5908-7-37.

Human Behavior Change Project. The Theory and Techniques Tool. https://theoryandtechniquetoolhumanbehaviourchangeorg/ Accessed 2.12.2024.

Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduction Journal. 2018;15(1):55;10.1186/s12954-018-0263-5.

Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T et al. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS Behav. 2018;22(4):1228-38;10.1007/s10461-017-1851-1.

Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1). https://doi.org/10.7448/IAS.19.1.20903.

Towe SL, Sullivan CA, McKellar MS, Meade CS. Examining the Potential of Pre-exposure Prophylaxis (PrEP) for HIV Prevention in a Community Sample of Persons Who Use Stimulants Living in the Southern United States. AIDS Behav. 2021;25(5):1480-9;10.1007/s10461-020-02987-y.

Qin Y, Price C, Rutledge R, Puglisi L, Madden LM, Meyer JP. Women’s Decision-Making about PrEP for HIV Prevention in Drug Treatment Contexts. J Int Assoc Provid AIDS Care. 2020;19:2325958219900091;10.1177/2325958219900091.

Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694 – 700;10.1007/s10461-014-0778-z.

Underhill K, Morrow KM, Colleran CM, Holcomb R, Operario D, Calabrese SK et al. Access to healthcare, HIV/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the US. PLoS One. 2014;9(11):e112425;10.1371/journal.pone.0112425.

Shrestha R, Altice F, Karki P, Copenhaver M. Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Front Immunol. 2017;8:561;10.3389/fimmu.2017.00561.

Felsher M, Ziegler E, Amico KR, Carrico A, Coleman J, Roth AM. PrEP just isn’t my priority: Adherence challenges among women who inject drugs participating in a pre-exposure prophylaxis (PrEP) demonstration project in Philadelphia, PA USA. Soc Sci Med. 2021;275:113809;10.1016/j.socscimed.2021.113809.

Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prev Policy. 2015;10:1;10.1186/1747-597x-10-1.

Smith DK, Mendoza MC, Stryker JE, Rose CE. PrEP Awareness and Attitudes in a National Survey of Primary Care Clinicians in the United States, 2009–2015. PLoS One. 2016;11(6):e0156592;10.1371/journal.pone.0156592.

Felsher M, Ziegler E, Smith LR, Sherman SG, Amico KR, Fox R et al. An Exploration of Pre-exposure Prophylaxis (PrEP) Initiation Among Women Who Inject Drugs. Arch Sex Behav. 2020;49(6):2205-12;10.1007/s10508-020-01684-0.

Calabrese SK, Tekeste M, Mayer KH, Magnus M, Krakower DS, Kershaw TS et al. Considering Stigma in the Provision of HIV Pre-Exposure Prophylaxis: Reflections from Current Prescribers. AIDS Patient Care STDS. 2019;33(2):79–88;10.1089/apc.2018.0166.

Oldenburg CE, Mitty JA, Biello KB, Closson EF, Safren SA, Mayer KH et al. Differences in Attitudes About HIV Pre-Exposure Prophylaxis Use Among Stimulant Versus Alcohol Using Men Who Have Sex with Men. AIDS Behav. 2016;20(7):1451-60;10.1007/s10461-015-1226-4.

Grov C, Rendina HJ, John SA, Parsons JT. Determining the Roles that Club Drugs, Marijuana, and Heavy Drinking Play in PrEP Medication Adherence Among Gay and Bisexual Men: Implications for Treatment and Research. AIDS Behav. 2019;23(5):1277-86;10.1007/s10461-018-2309-9.

Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians. Clin Infect Dis. 2016;62(1):99–105;10.1093/cid/civ736.

Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017;173:107 – 16;10.1016/j.drugalcdep.2016.12.023.

Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40;10.1186/s12954-017-0166-x.

Teitelman AM, Chittamuru D, Koblin BA, Davis A, Brawner BM, Fiore D et al. Beliefs Associated with Intention to Use PrEP Among Cisgender U.S. Women at Elevated HIV Risk. Arch Sex Behav. 2020;49(6):2213-21;10.1007/s10508-020-01681-3.

Krakower DS, Ware NC, Maloney KM, Wilson IB, Wong JB, Mayer KH. Differing Experiences with Pre-Exposure Prophylaxis in Boston Among Lesbian, Gay, Bisexual, and Transgender Specialists and Generalists in Primary Care: Implications for Scale-Up. AIDS Patient Care STDS. 2017;31(7):297–304;10.1089/apc.2017.0031.

Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83;10.1097/QAI.0b013e31818d5a27.

Chan PA, Patel RR, Mena L, Marshall BD, Rose J, Sutten Coats C et al. Long-term retention in pre-exposure prophylaxis care among men who have sex with men and transgender women in the United States. J Int AIDS Soc. 2019;22(8):e25385;10.1002/jia2.25385.

Peitzmeier SM, Tomko C, Wingo E, Sawyer A, Sherman SG, Glass N et al. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. AIDS Care. 2017;29(11):1453-7;10.1080/09540121.2017.1300628.

Roth AM, Tran NK, Felsher M, Gadegbeku AB, Piecara B, Fox R et al. Integrating HIV Preexposure Prophylaxis With Community-Based Syringe Services for Women Who Inject Drugs: Results From the Project SHE Demonstration Study. J Acquir Immune Defic Syndr. 2021;86(3):e61-e70;10.1097/qai.0000000000002558.

Bartholomew TS, Andraka-Cristou B, Totaram RK, Harris S, Doblecki-Lewis S, Ostrer L et al. We want everything in a one-stop shop: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. Harm Reduction Journal. 2022;19(1):133;10.1186/s12954-022-00721-6.

Meyer J, Price C, Tracey D, Sharpless L, Song Y, Madden L et al. Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders. Patient Preference and Adherence. 2021;15:1913-27;10.2147/PPA.S315543.

Richterman A, Ghadimi F, Teitelman AM, Moore K, Acri T, North H et al. Acceptability and Feasibility of a Mobile Phone Application to Support HIV Pre-exposure Prophylaxis Among Women with Opioid Use Disorder. AIDS and Behavior. 2023;10.1007/s10461-023-04060-w.

Shrestha R, Altice FL, Karki P, Copenhaver MM. Integrated Bio-behavioral Approach to Improve Adherence to pre-exposure Prophylaxis and reduce HIV risk in people who use drugs: a pilot feasibility study. AIDS Behav. 2018;22(8):2640–9. https://doi.org/10.1007/s10461-018-2099-0.

Article  PubMed  PubMed Central  Google Scholar 

Des Jarlais DC, Arasteh K, Perlis T, Hagan H, Abdul-Quader A, Heckathorn DD, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. Aids. 2007;21(2):231–5.

Article  PubMed  Google Scholar 

Wang SC, Maher B. Substance Use Disorder, Intravenous Injection, and HIV Infection: A Review. Cell Transplant. 2019;28(12):1465-71;10.1177/0963689719878380.

Scheibe A, Young K, Versfeld A, Spearman CW, Sonderup MW, Prabdial-Sing N, et al. Hepatitis B, Hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017). BMC Infect Dis. 2020;20:1–15.

Article  Google Scholar 

Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99–106;10.1007/s11904-010-0043-7.

Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006;83(6):1151-7;10.1007/s11524-006-9119-5.

Scheibein F, Wells J, Henriques S, Van Hout MC. Slam sex-sexualized injecting drug use (SIDU) amongst men who have sex with men (MSM)—a scoping review. J Homosex. 2021;68(14):2344–58.

Article  PubMed  Google Scholar 

Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs’ role in ending the HIV epidemic in the US: why we cannot do it without them. Am J Prev Med. 2021;61(5):S118–29.

Article  PubMed  Google Scholar 

Bunting SR, Saqueton R, Batteson TJ. A Guide for Designing Student-Led, Interprofessional Community Education Initiatives About HIV Risk and Pre-Exposure Prophylaxis. MedEdPORTAL. 2019;15:10818;10.15766/mep_2374-8265.10818.

Centers for Disease Control and Prevention. Prevention research synthesis (PRS) compendium intervention search. https://www.ncdcgov/HIVCompendium/SearchInterventions Accessed 1/9/24.

Maskay MH, Cabral HJ, Davila JA, Whitlock Davich JA, Marcus R, Quinn EK et al. Longitudinal Stigma Reduction in People Living with HIV Experiencing Homelessness or Unstable Housing Diagnosed With Mental Health or Substance Use Disorders: An Intervention Study. Am J Public Health. 2018;108(S7):S546-s51;10.2105/ajph.2018.304774.

Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K et al. The Influence of Housing Status on the HIV Continuum of Care: Results From a Multisite Study of Patient Navigation Models to Build a Medical Home for People Living With HIV Experiencing Homelessness. Am J Public Health. 2018;108(S7):S539-s45;10.2105/ajph.2018.304736.

Curran GM, Landes SJ, McBain SA, Pyne JM, Smith JD, Fernandez ME et al. Reflections on 10 years of effectiveness-implementation hybrid studies. Frontiers in Health Services. 2022;2;10.3389/frhs.2022.1053496.

Damschroder LJ, Reardon CM, Opra Widerquist MA, Lowery J. Conceptualizing outcomes for use with the Consolidated Framework for Implementation Research (CFIR): the CFIR Outcomes Addendum. Implementation Science. 2022;17(1):7;10.1186/s13012-021-01181-5.

Smith JD, Li DH, Rafferty MR. The Implementation Research Logic Model: a method for planning, executing, reporting, and synthesizing implementation projects. Implementation Science. 2020;15(1);10.1186/s13012-020-01041-8.

Geng EH, Nash D, Phanuphak N, Green K, Solomon S, Grimsrud A et al. The question of the question: impactful implementation science to address the HIV epidemic. J Int AIDS Soc. 2022;25(4):e25898;10.1002/jia2.25898.